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Abstract
Background: Reactivated cytomegalovirus (CMV) infection has been known to cause significant morbidity and
mortality in immunocompromised patients. However, CMV disease rarely develops in immunocompetent patients,
and reported cases often present with a mild, self-limiting course, without severe life-threatening sequelae. While
the colon is the most common gastrointestinal site affected by CMV disease in immunocompetent patients, rectal
involvement is rarely reported. CMV proctitis can present in two distinct forms, primary and reactivated. However,
reactivated CMV proctitis is rarely reported as a causative etiology of nosocomial diarrhea, except in transplant
patients. Herein we present a case of reactivated CMV proctitis in an immunocompetent patient, presenting as
nosocomial diarrhea. Previously reported cases of reactivated CMV proctitis in immunocompetent patients are also
reviewed.
Case presentation: A 79-year-old female was admitted because of metabolic encephalopathy caused by
dehydration and hypernatremia. The patient’s consciousness level returned rapidly after fluid supplementation.
However, she subsequently presented with abdominal pain and diarrhea on day 8 of admission. Abdominal
contrast-enhanced computed tomography on day 10 of admission demonstrated inflammation around the rectum,
suggesting proctitis. Colonoscopy on day 16 of admission showed a giant ulcer at the rectum. Pathology of rectal
biopsy confirmed CMV infection. The patient recovered without sequelae after 38 days of valganciclovir treatment.
Follow-up colonoscopy revealed a healed ulcer over the rectum. Ten cases in the literature, plus our case, with
reactivated CMV proctitis in immunocompetent patients were reviewed. We found that most patients were elderly
(mean, 72 years) with a high prevalence of diabetes mellitus (54.5%). Cardinal manifestations are often non-specific
(diarrhea, hematochezia, tenesmus), and eight (72.7%) developed CMV proctitis following a preceding acute, life-
threatening disease, rather than as an initial presentation on admission. These manifestations frequently develop
during hospitalization, and are thus often regarded as nosocomial diarrhea.
Conclusions: Clinicians should be aware of the possibility of nosocomial onset of reactivated CMV proctitis in
patients hospitalized due to a preceding critical illness, although the benefits of antiviral therapy remain unclear.
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Background
Cytomegalovirus (CMV) is a member of the Herpes
virus family, and CMV disease can lead to significant
morbidity and mortality in immunocompromised pa-
tients [1]. Through direct and indirect mechanisms,
CMV can cause mononucleosis-like syndrome, tissue
invasive disease, opportunistic infection, and post-
transplant lymphoproliferative disorder in immuno-
compromised patients [1]. However, CMV disease
rarely develops in immunocompetent patients, and re-
ported cases often present with a mild, self-limiting
course, without severe life-threatening sequelae [2].
A recent review of 290 cases of CMV disease in im-
munocompetent patients demonstrated the gastrointes-
tinal (GI) tract to be the most commonly involved site,
occurring in 91 patients (31%) [2]. While the colon is
the site of the GI tract most commonly affected, the rec-
tum is rarely involved [2]. CMV proctitis can present in
two distinct forms: primary and reactivated [3].
Mononucleosis-like illness with rectal bleeding within
several days to 2 weeks after unprotected anal inter-
course in young patients is pathognomonic for primary
CMV proctitis [3]. In contrast, reactivated CMV procti-
tis mainly occurs in elderly patients, without exposure to
anal intercourse, who have multiple comorbidities, such
as diabetes mellitus (DM), inflammatory bowel disease,
and multi-organ failure [3]. However, CMV reactivation
is rarely reported as a causative etiology of nosocomial
diarrhea, except in transplant patients [4, 5].
We present here a case of reactivated CMV proctitis
in an immunocompetent patient, presenting as nosoco-
mial diarrhea, and previously reported cases of reacti-
vated CMV proctitis in immunocompetent patients are
also reviewed.
Case presentation
A 79-year-old female with underlying diseases of DM,
major depression disorder, and coronary heart disease
was admitted because of altered mental status for 5 days.
She could take care of herself until 5 days before admis-
sion. However, at this time, her family found that she
could not recognize them. She had no fever, chills, or
gastrointestinal discomfort.
She was initially hospitalized under a diagnosis of al-
tered mental status with the suspicion of metabolic
encephalopathy or central nervous system (CNS) in-
fection. On admission, the patient was dehydrated
with tachycardia. Her Glasgow Coma Scale (GCS)
score for consciousness was E3V4M5. No other sign
of cranial nerve dysfunction or decreased muscle
power was noted and the remainder of the physical
examination was unremarkable.
Laboratory investigation including blood counts, elec-
trolytes, and renal and liver function test were normal
except for hemoconcentration (blood urea nitrogen,
26.7 mg/dL; serum creatinine, 1.52 mg/dL; Na+,
153 mmol/L). To evaluate the causes of altered mental
status, lumbar puncture was performed with the follow-
ing results: cell count, 0/cumm; glucose, 100 mg/dL;
polymerase chain reaction (PCR) for herpes simplex
virus (HSV), negative. Cerebrospinal fluid (CSF) culture
for bacteria, Mycobacterium, fungi and virus proved to
be negative. Brain contrast-enhanced magnetic reson-
ance imaging revealed senile brain atrophy without evi-
dence of encephalitis or meningeal inflammation.
Under a presumptive diagnosis of metabolic encephal-
opathy or CNS infection, acyclovir and ceftriaxone were
prescribed for 5 days until negative CSF results (bacterial
culture and HSV PCR) were confirmed. The patient’s con-
sciousness level returned rapidly to GCS E4V5M6 after
fluid supplementation for initial dehydration. However,
she subsequently presented with abdominal pain and diar-
rhea on day 8 of admission. We initially treated the patient
for nosocomial diarrhea, including adjusting her enteral
feeding diet and medication, and surveying the stool for
Clostridium difficile infection. However, stool analysis dis-
closed negativity for fecal white blood cells and C. difficile
toxins A and B, but positivity for occult blood. Because of
persistent GI discomfort, abdominal contrast-enhanced
computed tomography was performed on day 10 of ad-
mission, which demonstrated inflammation around the
rectum, suggesting proctitis (Fig. 1).
Colonoscopy was performed on day 16 of admission,
which showed a giant ulcer with mucus coating at the
rectum (Fig. 2a). Pathology of a rectal biopsy at 10 cm
above the anal verge confirmed CMV proctitis (Fig. 3a
and b). Serological tests to detect CMV immunoglobulin
(Ig) G and IgM antibodies were positive and negative,
respectively. HIV enzyme-linked immunosorbent assay
and a CMV pp65 antigen test were both negative.
Fig. 1 Abdominal contrast-enhanced computed tomography (CT)
and histopathology. Abdominal contrast-enhanced CT on day 10 of
admission revealed increased inflammation surrounding the rectum,
suggestive of proctitis (arrow)
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The patient received 450 mg of valganciclovir twice
daily for 38 days and her intestinal discomfort, including
abdominal pain and diarrhea, improved completely.
Follow-up colonoscopy performed after 38 days of val-
ganciclovir treatment revealed a healed ulcer over the
rectum (Fig. 2b).
Discussion
We performed a literature search of articles published
from 1980 to 2015 using the PubMed database with the
search terms “CMV proctitis,” “cytomegalovirus,” and
“proctitis”. References from relevant articles were also
reviewed for potential cases. Only cases of reactivated
CMV proctitis in immunocompetent patients were in-
cluded. Although reactivation of CMV frequently occurs
in aging, it is subclinical in the majority [6]. Therefore,
although elderly individuals are less immunocompetent
than young population [6], they are not considered to be
profoundly immunocompromised in our literature view.
Immunocompetent patients were defined as patients
without profound loss of immune function, thus we ex-
cluded AIDS patients, solid organ or hematopoietic stem
cell transplant recipients, or patients receiving immuno-
suppressive agents. A total of 11 cases (including the
present case) of reactivated CMV proctitis in
immunocompetent patients were identified from five
published articles. Comorbidities, clinical manifestation,
endoscopic findings, therapeutic interventions and out-
comes were analyzed (Table 1).
In our review of 11 cases, the mean age was 72 years
(range, 57–92 years); three (27.3%) were male; six
(54.5%) had DM; eight (72.7%) initially presented with
preceding conditions unrelated to CMV proctitis; five
(45.5%) died. Among the 11 cases, five patients (45.5%)
received ganciclovir or valganciclovir, and local compli-
cations related to proctitis developed in five patients
(45.5%) (massive rectal bleeding, n = 1; rectal fistula to
adjacent organs, n = 3; rectal stricture, n = 1).
In our review, 72.7% of CMV proctitis cases occurred
during hospitalization for a preceding condition, rather
than as an initial presentation on admission. Cardinal
manifestations are often non-specific (e.g., diarrhea,
hematochezia, tenesmus), and these presentations, while
developing during hospitalization, are often regarded as
nosocomial diarrhea. Nosocomial diarrhea, however, is a
common complication of hospitalization that is generally
caused by non-infectious etiologies, such as medications
and enteral feeding. C. difficile is the most common in-
fectious etiology of nosocomial diarrhea [4], while CMV
as an etiology of nosocomial diarrhea is reported mainly
Fig. 2 Colonoscopy before and after antiviral therapy. a Colonoscopy on day 16 of admission revealed a giant ulcer with mucosal coating at the
rectum (arrow). b Colonoscopy after 38 days of valganciclovir treatment revealed a healed ulcer over the rectum (arrow)
Fig. 3 Microscopic examination of rectal biopsy. a Hematoxylin and eosin staining (x 400) revealed ulcerative colonic mucosa with granulation
tissue and scattered atypical cells (arrow) bearing basophilic intranuclear inclusion bodies with perinuclear halo (asterisk). b Immunohistochemical
staining with monoclonal antibodies for CMV (x 400) demonstrated positive uptake in inclusion bodies (arrow)
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in transplant patients [4, 5]. Based on our findings,
therefore, CMV proctitis should also be included in the
differential diagnosis in a staged approach of diagnosing
nosocomial diarrhea in hospitalized adults, especially for
aged patients with DM.
We found that 72.7% of patients developed reactivated
CMV proctitis following a preceding acute, life-
threatening disease. This finding, however, was also ob-
served in previous reports of CMV colitis in immuno-
competent patients [7, 8]. In a previous review, CMV
diseases were reported in 0–36% of critically ill immuno-
competent patients, mostly developing 4–12 days after
ICU admission [9]. Disruption of the colonic mucosa
caused by preceding conditions, such as medication, in-
flammatory bowel disease, radiation therapy, and cardio-
genic shock, may result in CMV reactivation [8–10].
Sepsis may also lead to CMV reactivation through the
inability of interleukin-2 to restore natural killer cell
function, which is important in controlling the virus
after acute infection and reactivation [11]. Complex in-
teractions among the inflammatory cascade, the reacti-
vation stimulus, and viral load on the pathogenesis of
CMV reactivation in immunocompetent patients require
further investigation [11].
CMV proctitis and colitis may not be regarded as two
distinctive disease entities because these two sites of in-
volvement often occur concomitantly [2, 10, 12, 13]. How-
ever, compared with previous studies of CMV colitis in
immunocompetent patients by Polymnia et al. (mean age,
61.1 years; DM, 13.6%) [14] and Karakozis et al. (mean
age, 63 years) [15], the 11 cases in our review appeared to
be older (mean age, 72 years) and had a higher prevalence
of DM (54.5%). These findings imply that immunocompe-
tent patients with more vulnerable factors affecting im-
mune responses are more prone to CMV proctitis with or
without colitis than to CMV colitis alone.
The significance of negative CMV pp65 antigenemia
in the present case with confirmed CMV proctitis re-
mains unknown. CMV pp65 antigen in polymorpho-
nuclear leukocytes is used to detect CMV viremia. There
have been several studies to evaluate the utility of CMV
pp65 antigenemia as an indicator for pre-emptive ther-
apy in the immunocompromised host, such as transplant
and AIDS patients [16, 17]. The cut-off for CMV pp65
antigenemia to start pre-emptive therapy varies among
different patient populations [16], but the relevant
threshold in the immunocompetent host is lacking. Be-
sides, it is not uncommon to observe negative CMV
pp65 antigenemia in immunocompromised patients with
confirmed CMV disease [18], and the relevant data
about the prevalence of negative CMV pp65 antigenemia
in immunocompetent hosts with confirmed CMV dis-
ease is also absent. In summary, the utility of CMV pp65
antigen testing in immunocompetent hosts as an
indicator for pre-emptive therapy or diagnosis of CMV
disease requires further investigation.
In our review, one of five patients receiving antiviral
therapy died (related to local complications of proctitis);
and four of six patients without antiviral therapy died
(one case related to CMV proctitis). Though there is a
difference in the overall mortality rate between those
with and without antiviral treatment, unlike the defini-
tive role of antiviral therapy in the management of CMV
disease in immunocompromised patients [1, 19, 20], no
clear conclusion can be drawn about the benefit of anti-
viral therapy for CMV proctitis in immunocompetent
patients based on this small, non-controlled study. A
previous review of severe CMV infection in immuno-
competent patients also revealed inconclusive results [2].
The improvement observed in some of the patients re-
ceiving antiviral agents may be related to the typically
self-limiting course of CMV disease in immunocompe-
tent hosts, rather than to any antiviral effect [2]. Consid-
ering the rarity of reactivated CMV disease in
immunocompetent patients, it is difficult to conduct a
randomized controlled trial. Therefore, in immunocom-
petent patients, the potential benefit of antiviral treat-
ment should be cautiously weighed against the potential
toxicity of antiviral therapy.
Conclusions
In conclusion, reactivated CMV proctitis in immuno-
competent patients is rare, and has been reported mainly
in elderly patients with comorbidities, especially DM.
We believe reactivated CMV proctitis is an important,
but underestimated etiology of nosocomial diarrhea. Cli-
nicians should be aware of the possibility of nosocomial
onset of reactivated CMV proctitis in patients hospital-
ized due to a preceding, critical illness, although the
benefits of antiviral therapy remain unclear.
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